Literature DB >> 20434491

Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.

Emma L Lane1, Stephen B Dunnett.   

Abstract

L-dopa induced dyskinesia is a complication of long-term L-dopa administration in patients with Parkinson's disease. This study uses the rodent model of dyskinesia to determine whether prior dopamine agonist treatment causes long-term changes that influence the development of L-dopa mediated behaviours. Rats with unilateral 6-OHDA lesions were injected with dopamine agonists (ropinirole, piribedil bromocriptine, all 1mg/kg) or saline (0.9%) daily for 21 days. Following a 1-week drug free interval L-dopa was administered for 15 days (10mg/kg with benserazide 15 mg/kg in saline s.c.). Rotational behaviour and abnormal involuntary movements (AIMs) were recorded at regular intervals. All dopamine agonists induced a contralateral rotational response on day 1, which increased in response to repeated administration but did not by themselves induce overt dyskinesias. On day 1 of L-dopa administration animals pre-treated with piribedil and ropinirole produced a more severe rotational response. In the saline pre-treated group, AIMs developed with repeated L-dopa administration, which was reflected in the increased expression of PPE-B mRNA. There was a trend for the same pattern in the dopamine agonist treated groups but this was non-significant. Therefore, while locomotor sensitivity is altered by the pre-treatment with dopamine agonists, there appears to be no increased risk of developing AIMs. (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434491     DOI: 10.1016/j.bbr.2010.04.034

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  6 in total

1.  The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.

Authors:  Manfred Gerlach; Paul Halley; Peter Riederer; Maarten van den Buuse
Journal:  J Neural Transm (Vienna)       Date:  2012-05-17       Impact factor: 3.575

2.  D1 Antagonists and D2 Agonists Have Opposite Effects on the Metabolism of Dopamine in the Rat Striatum.

Authors:  Alberto Avila-Luna; Jacqueline Prieto-Leyva; Arturo Gálvez-Rosas; Alfonso Alfaro-Rodriguez; Rigoberto Gonzalez-Pina; Antonio Bueno-Nava
Journal:  Neurochem Res       Date:  2015-05-17       Impact factor: 3.996

3.  Increased motor impulsivity in a rat gambling task during chronic ropinirole treatment: potentiation by win-paired audiovisual cues.

Authors:  Melanie Tremblay; Michael M Barrus; Paul J Cocker; Christelle Baunez; Catharine A Winstanley
Journal:  Psychopharmacology (Berl)       Date:  2019-01-31       Impact factor: 4.530

Review 4.  Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

5.  Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.

Authors:  Corinne Y Ostock; David Lindenbach; Adam A Goldenberg; Elias Kampton; Christopher Bishop
Journal:  Behav Brain Res       Date:  2014-05-13       Impact factor: 3.332

6.  Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.

Authors:  Rhyomi C Sellnow; Kathy Steece-Collier; Feras Altwal; Ivette M Sandoval; Jeffrey H Kordower; Timothy J Collier; Caryl E Sortwell; Anthony R West; Fredric P Manfredsson
Journal:  J Neurosci       Date:  2020-04-01       Impact factor: 6.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.